Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'antimigraine' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 140 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Slassi, A; Isaac, M; Arora, J
      Novel serotonergic and non-serotonergic migraine headache therapies

      EXPERT OPINION ON THERAPEUTIC PATENTS
    2. Thomsen, LL; Olesen, J
      Nitric oxide in primary headaches

      CURRENT OPINION IN NEUROLOGY
    3. Eadie, MJ
      Clinically significant drug interactions with agents specific for migraineattacks

      CNS DRUGS
    4. Williamson, DJ; Hargreaves, RJ
      Neurogenic inflammation in the context of migraine

      MICROSCOPY RESEARCH AND TECHNIQUE
    5. Cipolla, G; Sacco, S; Crema, F; Moro, E; De Ponti, F; Frigo, G
      Gastric motor effects of triptans: Open questions and future perspectives

      PHARMACOLOGICAL RESEARCH
    6. Oh, SJ; Ha, HJ; Chi, DY; Lee, HK
      Serotonin receptor and transporter ligands - Current status

      CURRENT MEDICINAL CHEMISTRY
    7. Xu, XH; Bartlett, MG; Stewart, JT
      Determination of degradation products of sumatriptan succinate using LC-MSand LC-MS-MS

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    8. Goadsby, PJ; Akerman, S; Storer, RJ
      Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex

      ANNALS OF NEUROLOGY
    9. Terron, JA; Bouchelet, I; Hamel, E
      5-HT7 receptor mRNA expression in human trigeminal ganglia

      NEUROSCIENCE LETTERS
    10. Carruthers, AM; Sellers, LA; Jenkins, DW; Jarvie, EM; Feniuk, W; Humphrey, PPA
      Adenosine A(1) receptor-mediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons

      MOLECULAR PHARMACOLOGY
    11. Willems, EW; Valdivia, LF; Ramirez-San Juan, E; Saxena, PR; Villalon, CM
      Pharmacological identification of the major subtypes of adrenoceptors involved in the canine external carotid vasoconstrictor effects of adrenaline and noradrenaline

      LIFE SCIENCES
    12. Bingham, S; Davey, PT; Sammons, M; Raval, P; Overend, P; Parsons, AA
      Inhibition of inflammation-induced thermal hypersensitivity by sumatriptanthrough activation of 5-HT1B/1D receptors

      EXPERIMENTAL NEUROLOGY
    13. Parsons, AA; Bingham, S; Raval, P; Read, S; Thompson, M; Upton, N
      Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes

      BRITISH JOURNAL OF PHARMACOLOGY
    14. Gras, J; Llupia, J; Llenas, J; Palacios, JM
      Safety profile of almotriptan, a new antimigraine agent - Effects on central nervous system, renal function and respiratory dynamics

      ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
    15. Uddman, R; Longmore, J; Cardell, LO; Edvinsson, L
      Expression of 5-HT1B receptors in human nasal mucosa

      ACTA OTO-LARYNGOLOGICA

    16. 5-bicycloindoles as 5HT(1D) agonists - Allelix Biopharmaceuticals, Inc.: WO0004019

      EXPERT OPINION ON THERAPEUTIC PATENTS
    17. Goadsby, PJ; Peatfield, R
      Zolmitriptan in the acute treatment of migraine: An overview

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    18. Edmeads, J; Johnson, FN
      The adverse event and tolerability profile of zolmitriptan

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    19. MaassenVanDenBrink, A; Reekers, M; Bax, WA; Saxena, PR
      Human isolated coronary artery contraction to sumatriptan characterised bythe selective 5-HT1B/1D receptor antagonist GR55562

      PHARMACOLOGY & TOXICOLOGY
    20. Hargreaves, RJ
      Pharmacology and potential mechanisms of action of rizatriptan

      CEPHALALGIA
    21. Longmore, J; Maguire, JJ; MacLeod, A; Street, L; Schofield, WN; Hill, RG
      Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptoragonist L-775,606 with the mixed 5-HT1B/(1D)-receptor agonist sumatriptan and 5-HT in human isolated coronary artery

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    22. Goadsby, PJ; Hargreaves, RJ
      Mechanisms of action of serotonin 5-HT1B/1D agonists: Insights into migraine pathophysiology using rizatriptan

      NEUROLOGY
    23. Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J
      Regional differences of cerebrovascular reactivity effected by calcium channel blocker - Dotarizine

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    24. Manfredi, PL; Shenoy, S; Payne, R
      Sumatriptan for headache caused by head and neck cancer

      HEADACHE
    25. van den Broek, RWM; MaassenVanDenBrink, A; de Vries, R; Bogers, AJJC; Stegmann, APA; Avezaat, CJ; Saxena, PR
      Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels

      EUROPEAN JOURNAL OF PHARMACOLOGY
    26. Gupta, P; Butler, P; Shepperson, NB; McHarg, A
      The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT1B/1D receptor agonist

      EUROPEAN JOURNAL OF PHARMACOLOGY
    27. Tfelt-Hansen, P; De Vries, P; Saxena, PR
      Triptans in migraine - A comparative review of pharmacology, pharmacokinetics and efficacy

      DRUGS
    28. de Hoon, JNJM; Willigers, JM; Troost, J; Struijker-Boudier, HAJ; Van Bortel, LMAB
      Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    29. Dingemanse, J; Soubrouillard, C; Paris, J; Pisano, P; Blin, O
      Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorptionof IS-159, a peptide serotonin 1B/1D-receptor agonist

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    30. Heinz, A; Denke, C; Ernst, G
      Drug-induced headache - pathomechanisms of addiction

      SCHMERZ
    31. Nagain-Domaine, C; Presset, O; Chariot, J; Roze, C
      Effect of sumatriptan on external pancreatic secretion and its interactionwith endogenous norepinephrine in the rat

      PANCREAS
    32. Pauwels, PJ; John, GW
      Present and future of 5-HT receptor agonists as antimigraine drugs

      CLINICAL NEUROPHARMACOLOGY
    33. Hamel, E
      The biology of serotonin receptors: Focus on migraine pathophysiology and treatment

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    34. Razzaque, Z; Heald, MA; Pickard, JD; Maskell, L; Beer, MS; Hill, RG; Longmore, J
      Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    35. Hara, H; Shimazawa, M; Sasaoka, M; Yamada, C; Iwakura, Y; Sakai, T; Maeda, Y; Yamaguchi, T; Sukamoto, T; Hashimoto, M
      Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs

      CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
    36. Villalon, CM; Centurion, D; Sanchez-Lopez, A; De Vries, P; Saxena, P
      5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs

      ACTA PHARMACOLOGICA SINICA
    37. Cutrer, FM; Yu, XJ; Ayata, G; Moskowitz, MA; Waeber, C
      Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis

      NEUROPHARMACOLOGY
    38. Baezner, H; Steinke, W; Daffertshofer, M; Hennerici, M
      Vasoneuronal coupling in migraineurs after subcutaneous sumatriptan: a TCDstudy

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    39. John, GW; Pauwels, PJ; Perez, M; Halazy, S; Le Grand, B; Verscheure, Y; Valentin, JP; Palmier, C; Wurch, T; Chopin, P; Marien, M; Kleven, MS; Koek, W; Assie, MB; Carilla-Durand, E; Tarayre, JP; Colpaert, FC
      F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    40. Goadsby, PJ
      Understanding migraine pathophysiology through studying the mechanism of action of rizatriptan

      HEADACHE
    41. Nilsson, T; Longmore, J; Shaw, D; Pantev, E; Bard, JA; Branchek, T; Edvinsson, L
      Characterisation of 5-HT receptors in human coronary arteries by molecularand pharmacological techniques

      EUROPEAN JOURNAL OF PHARMACOLOGY
    42. Mitsikostas, DD; del Rio, MS; Moskowitz, MA; Waeber, C
      Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis

      EUROPEAN JOURNAL OF PHARMACOLOGY
    43. Gupta, P; Scatchard, J; Napier, C; McHarg, A; Wallis, R
      Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor

      EUROPEAN JOURNAL OF PHARMACOLOGY
    44. Spencer, CM; Gunasekara, NS; Hills, C
      Zolmitriptan - A review of its use in migraine

      DRUGS

    45. Zolmitriptan - New product similar to sumatriptan

      CANADIAN FAMILY PHYSICIAN
    46. Nilsson, T; Longmore, J; Shaw, D; Olesen, IJ; Edvinsson, L
      Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry

      BRITISH JOURNAL OF PHARMACOLOGY
    47. Terron, JA; Falcon-Neri, A
      Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries

      BRITISH JOURNAL OF PHARMACOLOGY
    48. De Vries, P; Willems, EW; Heiligers, JPC; Villalon, CM; Saxena, PR
      Investigation of the role of 5-HT1B and 5-HT1D receptors in the sumatriptan-induced constriction of porcine carotid arteriovenous anastomoses

      BRITISH JOURNAL OF PHARMACOLOGY
    49. DELEU D; HANSSENS F; WORTHING EA
      SYMPTOMATIC AND PROPHYLACTIC TREATMENT OF MIGRAINE - A CRITICAL REAPPRAISAL

      Clinical neuropharmacology
    50. DAHLOF CGH; MATHEW N
      CARDIOVASCULAR SAFETY OF 5HT(1B 1D) AGONISTS - IS THERE A CAUSE FOR CONCERN/

      Cephalalgia
    51. DAHLOF CGH; FALK L; RISENFORS M; LEWIS CP
      SAFETY TRIAL WITH THE 5HT(1B 1D) AGONIST AVITRIPTAN (BMS-180048) IN PATIENTS WITH MIGRAINE WHO HAVE EXPERIENCED PRESSURE, TIGHTNESS, AND/ORPAIN IN THE CHEST, NECK, AND/OR THROAT FOLLOWING SUMATRIPTAN/

      Cephalalgia
    52. SILBERSTEIN SD
      METHYSERGIDE

      Cephalalgia
    53. Longmore, J; Razzaque, Z; Shaw, D; Davenport, AP; Maguire, J; Pickard, JD; Schofield, WN; Hill, RG
      Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    54. GOADSBY PJ; HOSKIN KL; KNIGHT YE
      SUBSTANCE-P BLOCKADE WITH THE POTENT AND CENTRALLY ACTING ANTAGONIST GR205171 DOES NOT EFFECT CENTRAL TRIGEMINAL ACTIVITY WITH SUPERIOR SAGITTAL SINUS STIMULATION

      Neuroscience
    55. LEGRAND B; VIE B; JOHN GW
      EFFECTS OF SUMATRIPTAN ON CORONARY FLOW AND LEFT-VENTRICULAR FUNCTIONIN THE ISOLATED-PERFUSED GUINEA-PIG HEART

      Journal of cardiovascular pharmacology
    56. MARATHE PH; GREENE DS; KOLLIA GD; BARBHAIYA RH
      EVALUATION OF THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF AVITRIPTAN

      Biopharmaceutics & drug disposition
    57. MARATHE PH; GREENE DS; LEE JS; BARBHAIYA RH
      ASSESSMENT OF EFFECT OF FOOD, GENDER, AND INTRA-SUBJECT VARIABILITY IN THE PHARMACOKINETICS OF AVITRIPTAN

      Biopharmaceutics & drug disposition
    58. MARATHE PH; SANDEFER EP; KOLLIA GE; GREENE DS; BARBHAIYA RH; LIPPER RA; PAGE RC; DOLL WJ; RYO UY; DIGENIS GA
      IN-VIVO EVALUATION OF THE ABSORPTION AND GASTROINTESTINAL TRANSIT OF AVITRIPTAN IN FED AND FASTED SUBJECTS USING GAMMA-SCINTIGRAPHY

      Journal of pharmacokinetics and biopharmaceutics
    59. WILLEMS E; DEVRIES P; HEILIGERS JPC; SAXENA PR
      PORCINE CAROTID VASCULAR EFFECTS OF ELETRIPTAN (UK-116,044) - A NEW 5-HT1B 1D RECEPTOR AGONIST WITH ANTIMIGRAINE ACTIVITY/

      Naunyn-Schmiedeberg's archives of pharmacology
    60. ENNIS MD; GHAZAL NB; HOFFMAN RL; SMITH MW; SCHLACHTER SK; LAWSON CF; BINIM W; PREGENZER JF; SVENSSON KA; LEWIS RA; HALL ED; SUTTER DM; HARRIS LT; MCCALL RB
      ISOCHROMAN-6-CARBOXAMIDES AS HIGHLY SELECTIVE 5-HT1D AGONISTS - POTENTIAL NEW TREATMENT FOR MIGRAINE WITHOUT CARDIOVASCULAR SIDE-EFFECTS

      Journal of medicinal chemistry
    61. CUTLER NR; SALAZAR DE; JHEE SS; FULMOR IE; FORD N; SMITH RA; SRAMEK JJ
      PHARMACOKINETICS AND PHARMACODYNAMICS OF AVITRIPTAN IN PATIENTS WITH MIGRAINE AFTER ORAL DOSING

      Headache
    62. SAXENA PR; DEVRIES P; HEILIGERS JPC; BAX WA; VANDENBRINK AM; YOCCA FD
      BMS-181885, A 5-HT1B 1D RECEPTOR-LIGAND, IN EXPERIMENTAL-MODELS PREDICTIVE OF ANTIMIGRAINE ACTIVITY AND CORONARY SIDE-EFFECT POTENTIAL/

      European journal of pharmacology
    63. DEVRIES P; WILLEMS EW; HEILIGERS JPC; VILLALON CM; SAXENA PR
      THE ANTIMIGRAINE AGENT ALNIDITAN SELECTIVELY CONSTRICTS PORCINE CAROTID ARTERIOVENOUS ANASTOMOSES VIA 5-HT1B 1D RECEPTORS/

      European journal of pharmacology
    64. MacLennan, SJ; Cambridge, D; Whiting, MV; Marston, C; Martin, GR
      Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine

      EUROPEAN JOURNAL OF PHARMACOLOGY
    65. MARATHE PH; GREENE DS; KOLLIA GD; BARBHAIYA RH
      A PHARMACOKINETIC INTERACTION STUDY OF AVITRIPTAN AND PROPRANOLOL

      Clinical pharmacology and therapeutics
    66. VANDENBRINK AM; REEKERS M; BAX WA; FERRARI MD; SAXENA PR
      CORONARY SIDE-EFFECT POTENTIAL OF CURRENT AND PROSPECTIVE ANTIMIGRAINE DRUGS

      Circulation
    67. DEVRIES P; VILLALON CM; HEILIGERS JPC; SAXENA PR
      CHARACTERIZATION OF 5-HT RECEPTORS MEDIATING CONSTRICTION OF PORCINE CAROTID ARTERIOVENOUS ANASTOMOSES - INVOLVEMENT OF 5HT(1B 1D) AND NOVEL RECEPTORS/

      British Journal of Pharmacology
    68. LESAGE AS; WOUTERS R; VANGOMPEL P; HEYLEN L; VANHOENACKER P; HAEGEMAN G; LUYTEN WHML; LEYSEN JE
      AGONISTIC PROPERTIES OF ALNIDITAN, SUMATRIPTAN AND DIHYDROERGOTAMINE ON HUMAN 5-HT1B AND 5-HT1D RECEPTORS EXPRESSED IN VARIOUS MAMMALIAN-CELL LINES

      British Journal of Pharmacology
    69. VILLALON CM; DEVRIES P; SAXENA PR
      SEROTONIN RECEPTORS AS CARDIOVASCULAR TARGETS

      Drug discovery today
    70. GOADSBY PJ
      BENCH TO BEDSIDE - WHAT HAVE WE LEARNT RECENTLY ABOUT HEADACHE

      Current opinion in neurology
    71. FUJITA T
      RECENT SUCCESS STORIES LEADING TO COMMERCIALIZABLE BIOACTIVE COMPOUNDS WITH THE AID OF TRADITIONAL QSAR PROCEDURES

      Quantitative structure-activity relationships
    72. CUPINI LM; CALABRESI P; SILVESTRINI M; TROISI E; MATTEIS M; ARGIRO G; BERNARDI G
      PROLACTIN RESPONSE TO BROMOCRIPTINE IN FLUNARIZINE-TREATED MIGRAINOUSWOMEN

      Clinical neuropharmacology
    73. MARANHAO PA; MARTINSFERREIRA H; VINCENT MB; RIBEIRO LJC; NOVIS SAP
      SUMATRIPTAN BLOCKS SPREADING DEPRESSION IN ISOLATED CHICK RETINA

      Cephalalgia
    74. LONGMORE J; SHAW D; SMITH D; HOPKINS R; MCALLISTER G; PICKARD JD; SIRINATHSINGHJI DJS; BUTLER AJ; HILL RG
      DIFFERENTIAL DISTRIBUTION OF 5HT(1D)-IMMUNOREACTIVITY AND 5HT(1B)-IMMUNOREACTIVITY WITHIN THE HUMAN TRIGEMINO-CEREBROVASCULAR SYSTEM - IMPLICATIONS FOR THE DISCOVERY OF NEW ANTIMIGRAINE DRUGS

      Cephalalgia
    75. WILLIAMSON DJ; HARGREAVES RJ; HILL RG; SHEPHEARD SL
      SUMATRIPTAN INHIBITS NEUROGENIC VASODILATION OF DURAL BLOOD-VESSELS IN THE ANESTHETIZED RAT - INTRAVITAL MICROSCOPE STUDIES

      Cephalalgia
    76. GAIST D; ANDERSEN M; AARUP AL; HALLAS J; GRAM LF
      USE OF SUMATRIPTAN IN DENMARK IN 1994-5 - AN EPIDEMIOLOGIC ANALYSIS OF NATIONWIDE PRESCRIPTION DATA

      British journal of clinical pharmacology
    77. SCIBERRAS DG; POLVINO WJ; GERTZ BJ; CHENG HY; STEPANAVAGE M; WITTREICH J; OLAH T; EDWARDS M; MANT T
      INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST

      British journal of clinical pharmacology
    78. PREGENZER JF; ALBERTS GL; BOCK JH; SLIGHTOM JL; IM WB
      CHARACTERIZATION OF LIGAND-BINDING PROPERTIES OF THE 5-HT1D RECEPTORSCLONED FROM CHIMPANZEE, GORILLA AND RHESUS-MONKEY IN COMPARISON WITH THOSE FROM THE HUMAN AND GUINEA-PIG RECEPTORS

      Neuroscience letters
    79. MARATHE PH; GREENE DS; KOLLIA GD; BARBHAIYA RH
      THE EFFECTS OF AGE AND GENDER ON THE SINGLE-DOSE PHARMACOKINETICS OF AVITRIPTAN ADMINISTERED TO HEALTHY-VOLUNTEERS

      Journal of clinical pharmacology
    80. MARATHE PH; GREENE DS; BARBHAIYA RH
      DISPOSITION OF [C-14] AVITRIPTAN IN RATS AND HUMANS

      Drug metabolism and disposition
    81. SHEPHERD SL; WILLIAMSON DJ; BEER MS; HILL RG; HARGREAVES RJ
      DIFFERENTIAL-EFFECTS OF 5-HT1B 1D RECEPTOR AGONISTS ON NEUROGENIC DURAL PLASMA EXTRAVASATION AND VASODILATION IN ANESTHETIZED RATS/

      Neuropharmacology
    82. YU XJ; CUTRER FM; MOSKOWITZ MA; WAEBER C
      THE 5-HT1D RECEPTOR ANTAGONIST GR-127,935 PREVENTS INHIBITORY EFFECTSOF SUMATRIPTAN BUT NOT CP-122,288 AND 5-CT ON NEUROGENIC PLASMA EXTRAVASATION WITHIN GUINEA-PIG DURA-MATER

      Neuropharmacology
    83. SAXENA PR; DEVRIES P; WANG W; HEILIGERS JPC; VANDENBRINK AM; BAX WA; YOCCA FD
      EFFECTS OF AVITRIPTAN, A NEW 5-HT1B 1D RECEPTOR AGONIST, IN EXPERIMENTAL-MODELS PREDICTIVE OF ANTIMIGRAINE ACTIVITY AND CORONARY SIDE-EFFECT POTENTIAL/

      Naunyn-Schmiedeberg's archives of pharmacology
    84. BRODFUEHRER PR; CHEN BC; SATTELBERG TR; SMITH PR; REDDY JP; STARK DR; QUINLAN SL; REID JG
      AN EFFICIENT FISCHER INDOLE SYNTHESIS OF AVITRIPTAN, A POTENT 5-HT1D RECEPTOR AGONIST

      Journal of organic chemistry
    85. TOTARO R; DEMATTEIS G; MARINI C; BALDASSARRE M; CAROLEI A
      SUMATRIPTAN AND CEREBRAL BLOOD-FLOW VELOCITY CHANGES DURING MIGRAINE ATTACKS

      Headache
    86. DIENER HC; GENDOLLA A; JUPTNER M; KAUBE H; LIMMROTH V
      EMERGING TREATMENTS IN HEADACHE

      European neurology
    87. GOADSBY PJ; KNIGHT Y
      INHIBITION OF TRIGEMINAL NEURONS AFTER INTRAVENOUS ADMINISTRATION OF NARATRIPTAN THROUGH AN ACTION AT 5-HYDROXYTRYPTAMINE (5-HT1B 1D) RECEPTORS/

      British Journal of Pharmacology
    88. CLAYTON JS; GASKIN PJ; BEATTIE DT
      ATTENUATION OF FOS-LIKE IMMUNOREACTIVITY IN THE TRIGEMINAL NUCLEUS CAUDALIS FOLLOWING TRIGEMINOVASCULAR ACTIVATION IN THE ANESTHETIZED GUINEA-PIG

      Brain research
    89. MCCALL RB
      TRIGEMINAL GANGLION ELICITED INCREASES IN NUCLEUS TRIGEMINAL CAUDALISBLOOD-FLOW - A NOVEL MIGRAINE MODEL

      Brain research
    90. LIMMROTH V; CUTRER M; MOSKOWITZ MA
      NEUROTRANSMITTERS AND NEUROPEPTIDES IN HEADACHE

      Current opinion in neurology
    91. LIMMROTH V; MAY A; DIENER HC
      THE VALUE OF SUMATRIPTAN IN THE ACUTE TRE ATMENT OF MIGRAINE AND CLUSTER HEADACHE

      Nervenheilkunde
    92. NUTI A; LUCETTI C; PAVESE N; DELLAGNELLO G; ROSSI G; BONUCCELLI U
      LONG-TERM FOLLOW-UP AFTER FLUNARIZINE OR NIMODIPINE DISCONTINUATION IN MIGRAINE PATIENTS

      Cephalalgia
    93. CUTLER NR; CLAGHORN J; SRAMEK JJ; BLOCK G; PANEBIANCO D; CHENG H; OLAH TV; REINES SA
      PILOT-STUDY OF MK-462 IN MIGRAINE

      Cephalalgia
    94. MAY A; GIJSMAN HJ; WALLNOFER A; JONES R; DIENER HC; FERRARI MD
      ENDOTHELIN ANTAGONIST BOSENTAN BLOCKS NEUROGENIC INFLAMMATION, BUT ISNOT EFFECTIVE IN ABORTING MIGRAINE ATTACKS

      Pain
    95. STOJAKOWSKA A; KISIEL W
      PRODUCTION OF PARTHENOLIDE IN ORGAN-CULTURES OF FEVERFEW

      Plant cell, tissue and organ culture
    96. GOBEL H; STOLZE H; HEINZE A; DWORSCHAK M; HEUSS D; CHRISTIANI K; LINDNER V
      18-MONTH LONG-TERM ANALYSIS OF THE EFFECT IVENESS, SAFETY AND TOLERABILITY OF SUBCUTANEOUS SUMATRIPTAN IN ACUTE MIGRAINE TREATMENT

      Nervenarzt
    97. WIEDEMANN M; DELIMA VMF; HANKE W
      EFFECTS OF ANTIMIGRAINE DRUGS ON RETINAL SPREADING DEPRESSION

      Naunyn-Schmiedeberg's archives of pharmacology
    98. LIMMROTH V; MAY A; AUERBACH P; WOSNITZA G; EPPE T; DIENER HC
      CHANGES IN CEREBRAL BLOOD-FLOW VELOCITY AFTER TREATMENT WITH SUMATRIPTAN OR PLACEBO AND IMPLICATIONS FOR THE PATHOPHYSIOLOGY OF MIGRAINE

      Journal of the neurological sciences
    99. MARTIN GR
      INHIBITION OF THE TRIGEMINO-VASCULAR SYSTEM WITH 5-HT1D AGONIST DRUGS- SELECTIVELY TARGETING ADDITIONAL SITES OF ACTION

      European neurology
    100. SAXENA PR; DEVRIES P; HEILIGERS JPC; VANDENBRINK AM; BAX WA; BARF T; WIKSTROM H
      INVESTIGATIONS WITH GMC2021 IN EXPERIMENTAL-MODELS PREDICTIVE OF ANTIMIGRAINE ACTIVITY AND CORONARY SIDE-EFFECT POTENTIAL

      European journal of pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 05:34:37